BioNTech (BNTX)
(Delayed Data from NSDQ)
$87.21 USD
+0.50 (0.58%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $87.20 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Income Statements
Fiscal Year end for BioNTech SE Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 4,133 | 18,238 | 22,451 | 551 | 122 |
Cost Of Goods | 649 | 3,156 | 3,445 | 68 | 19 |
Gross Profit | 3,484 | 15,083 | 19,007 | 483 | 102 |
Selling & Adminstrative & Depr. & Amort Expenses | 2,737 | 1,763 | 924 | 577 | 305 |
Income After Depreciation & Amortization | 747 | 13,320 | 18,082 | -94 | -203 |
Non-Operating Income | 562 | 348 | 80 | 2 | 5 |
Interest Expense | 26 | 20 | 361 | 74 | 2 |
Pretax Income | 1,284 | 13,648 | 17,801 | -167 | -201 |
Income Taxes | 277 | 3,708 | 5,624 | -184 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1,007 | 9,940 | 12,177 | 17 | -201 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 1,007 | 9,940 | 12,177 | 17 | -201 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 946 | 13,450 | 18,171 | -50 | -165 |
Depreciation & Amortization (Cash Flow) | 198 | 130 | 89 | 44 | 38 |
Income After Depreciation & Amortization | 747 | 13,320 | 18,082 | -94 | -203 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 242.90 | 249.79 | 259.72 | 253.30 | 226.78 |
Diluted EPS Before Non-Recurring Items | 4.15 | 39.80 | 46.89 | 0.07 | -0.95 |
Diluted Net EPS (GAAP) | 4.15 | 39.79 | 46.89 | 0.07 | -0.95 |
Fiscal Year end for BioNTech SE Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1,605.27 | 974.44 | 182.86 | 1,370.73 |
Cost Of Goods | NA | 192.39 | 176.10 | 177.63 | 103.05 |
Gross Profit | NA | 1,412.88 | 798.34 | 5.23 | 1,267.69 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 833.43 | 718.78 | 619.46 | 565.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 579.45 | 79.56 | -614.23 | 702.43 |
Non-Operating Income | NA | 137.73 | 170.12 | 166.18 | 88.34 |
Interest Expense | NA | -8.86 | 2.18 | 1.42 | 31.13 |
Pretax Income | NA | 726.03 | 247.50 | -449.46 | 759.65 |
Income Taxes | NA | 225.41 | 72.71 | -241.85 | 220.58 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 500.62 | 174.80 | -207.61 | 539.06 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 500.62 | 174.80 | -207.61 | 539.06 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 241.00 | 239.70 | 241.01 | 244.98 |
Diluted EPS Before Non-Recurring Items | NA | 2.05 | 0.73 | -0.86 | 2.20 |
Diluted Net EPS (GAAP) | NA | 2.08 | 0.73 | -0.86 | 2.20 |